Trial · NCT04562090
Adverse events68
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 68
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Urinary tract infection | Infections and infestations | Mirabegron 25 mg (Never Up-titrated) | 1 | 44 | 1 |
| other | Urinary tract infection | Infections and infestations | Mirabegron 25 mg (Later Up-titrated to 50 mg) | 0 | 39 | 0 |
| other | Urinary tract infection | Infections and infestations | Mirabegron 50 mg (Up-titrated From 25 mg) | 3 | 39 | 3 |
| other | Urinary tract infection | Infections and infestations | Mirabegron 50 mg | 6 | 165 | 6 |
| serious | Myocardial ischaemia | Cardiac disorders | Mirabegron 25 mg (Never Up-titrated) | 0 | 44 | 0 |
| serious | Myocardial ischaemia | Cardiac disorders | Mirabegron 25 mg (Later Up-titrated to 50 mg) | 0 | 39 | 0 |
| serious | Myocardial ischaemia | Cardiac disorders | Mirabegron 50 mg (Up-titrated From 25 mg) | 1 | 39 | 1 |
| serious | Myocardial ischaemia | Cardiac disorders | Mirabegron 50 mg | 0 | 165 | 0 |
| serious | Abdominal discomfort | Gastrointestinal disorders | Mirabegron 25 mg (Never Up-titrated) | 0 | 44 | 0 |
| serious | Abdominal discomfort | Gastrointestinal disorders | Mirabegron 25 mg (Later Up-titrated to 50 mg) | 0 | 39 | 0 |
| serious | Abdominal discomfort | Gastrointestinal disorders | Mirabegron 50 mg (Up-titrated From 25 mg) | 0 | 39 | 0 |
| serious | Abdominal discomfort | Gastrointestinal disorders | Mirabegron 50 mg | 1 | 165 | 1 |
| serious | Gastritis erosive | Gastrointestinal disorders | Mirabegron 25 mg (Never Up-titrated) | 0 | 44 | 0 |
| serious | Gastritis erosive | Gastrointestinal disorders | Mirabegron 25 mg (Later Up-titrated to 50 mg) | 0 | 39 | 0 |
| serious | Gastritis erosive | Gastrointestinal disorders | Mirabegron 50 mg (Up-titrated From 25 mg) | 0 | 39 | 0 |
| serious | Gastritis erosive | Gastrointestinal disorders | Mirabegron 50 mg | 1 | 165 | 1 |
| serious | Gastrooesophageal reflux disease | Gastrointestinal disorders | Mirabegron 25 mg (Never Up-titrated) | 0 | 44 | 0 |
| serious | Gastrooesophageal reflux disease | Gastrointestinal disorders | Mirabegron 25 mg (Later Up-titrated to 50 mg) | 0 | 39 | 0 |
| serious | Gastrooesophageal reflux disease | Gastrointestinal disorders | Mirabegron 50 mg (Up-titrated From 25 mg) | 0 | 39 | 0 |
| serious | Gastrooesophageal reflux disease | Gastrointestinal disorders | Mirabegron 50 mg | 1 | 165 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04562090/events